Radiation-Induced Myelosuppression Treatment MarketThe global Radiation-Induced Myelosuppression Treatment Market is ...

Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar ...

On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 ...

On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose ...

The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with ...

Pfizer Inc. has announced that Patrizia Cavazzoni, M.D. will rejoin the company as Chief Medical Officer, Executive Vice ...

Subject to shareholder approval at the subsequent Annual General Meeting (AGM), the Board of Directors of Sanofi Consumer ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

经济观察网讯 2月25日，中国国家药监局药品审评中心（CDE）官网最新公示，赛诺菲（Sanofi）申报的 盐酸非索非那定口服混悬液 新适应症上市申请获得受理。此前非索非那定片已经在中国获批，用于治疗 过敏性鼻炎 及 慢性特发性荨麻疹 。

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.